Free Trial

Knight Therapeutics Q4 2022 Earnings Report

Knight Therapeutics logo
C$5.55 +0.05 (+0.91%)
As of 04:00 PM Eastern

Knight Therapeutics EPS Results

Actual EPS
C$0.02
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Knight Therapeutics Revenue Results

Actual Revenue
$81.66 million
Expected Revenue
$62.00 million
Beat/Miss
Beat by +$19.66 million
YoY Revenue Growth
N/A

Knight Therapeutics Announcement Details

Quarter
Q4 2022
Time
N/A

Conference Call Resources

Knight Therapeutics Earnings Headlines

Three new patents reveal Elon and Trump’s secret “Project America”
Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR! He says these 5 stocks are trading for less than $2 right now… But they could soon SOAR in Trump’s first 100 days.
Knight Therapeutics Inc. (GUD.TO)
Knight Therapeutics earnings: here's what to expect
Knight Therapeutics Inc. (KHTRF)
See More Knight Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Knight Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Knight Therapeutics and other key companies, straight to your email.

About Knight Therapeutics

Knight Therapeutics (TSE:GUD) develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma. The company provides Ladecvina for multiple myeloma and myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Palbocil for breast cancer; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Dolufevir for HIV infection; Exelon for dementia; and Ibsrela for irritable bowel syndrome with constipation. In addition, it offers Salofalk for ulcerative colitis; Ursofalk for biliary cirrhosis; Imvexxy for moderate to severe dyspareunia; Bijuva for vasomotor symptoms; Fibridoner for idiopathic pulmonary fibrosis; Toliscrin DPI for pseudomonas aeruginosa lung infection; Toliscrin 1-2 for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Further, it finances other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is headquartered in Montreal, Canada.

View Knight Therapeutics Profile

More Earnings Resources from MarketBeat